Literature DB >> 10415716

Engineering of selective TIMPs.

H Nagase1, Q Meng, V Malinovskii, W Huang, L Chung, W Bode, K Maskos, K Brew.   

Abstract

Differences in proteinase susceptibility between free TIMP-1 and the TIMP-1-MMP-3 complex and mutagenesis studies suggested that the residues around the disulfide bond between Cys1 and Cys70 in TIMP-1 may interact with MMPs. The crystal structure of the complex between TIMP-1 and the catalytic domain of MMP-3 has revealed that the alpha-amino group of Cys1 bidentately chelates the catalytic zinc of MMP-3 and the Thr2 side chain occupies the S1' pocket. Generation of the N-terminal domain of TIMP-1 (N-TIMP-1) variants with 15 different amino acid substitutions for Thr2 has indicated that the nature of the side chain of residue 2 has a major effect on the affinity of N-TIMP-1 for three different MMPs (MMPs-1, -2 and -3). The results also demonstrate that the mode of binding of N-TIMP-1 residue 2 differs from the binding of the P1' residue of a peptide substrate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415716     DOI: 10.1111/j.1749-6632.1999.tb07670.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  14 in total

1.  Production and Roles of Glial Tissue Inhibitor of Metalloproteinases-1 in Human Immunodeficiency Virus-1-Associated Dementia Neuroinflammation: A Review.

Authors:  C Chao; A Ghorpade
Journal:  Am J Infect Dis       Date:  2009

2.  Conformational analyses of thiirane-based gelatinase inhibitors.

Authors:  Mijoon Lee; Dusan Hesek; Qicun Shi; Bruce C Noll; Jed F Fisher; Mayland Chang; Shahriar Mobashery
Journal:  Bioorg Med Chem Lett       Date:  2007-12-05       Impact factor: 2.823

3.  Selective inhibition of matrix metalloproteinase 10 (MMP10) with a single-domain antibody.

Authors:  Amir S Razai; Brendan P Eckelman; Guy S Salvesen
Journal:  J Biol Chem       Date:  2020-01-17       Impact factor: 5.157

4.  A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition.

Authors:  Mijoon Lee; Giuseppe Celenza; Bill Boggess; Jennifer Blase; Qicun Shi; Marta Toth; M Margarida Bernardo; William R Wolter; Mark A Suckow; Dusan Hesek; Bruce C Noll; Rafael Fridman; Shahriar Mobashery; Mayland Chang
Journal:  Chem Biol Drug Des       Date:  2009-02       Impact factor: 2.817

Review 5.  Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.

Authors:  Wanqiu Chen; Eun-Jung Choi; Cameron M McDougall; Hua Su
Journal:  Transl Stroke Res       Date:  2014-04-12       Impact factor: 6.829

6.  TIMP-1 Promotes the Immune Response in Influenza-Induced Acute Lung Injury.

Authors:  Jenieke R Allen; Lingyin Ge; Ying Huang; Rena Brauer; Tanyalak Parimon; Suzanne L Cassel; Fayyaz S Sutterwala; Peter Chen
Journal:  Lung       Date:  2018-08-30       Impact factor: 2.584

Review 7.  Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system.

Authors:  Jessica Gardner; Anuja Ghorpade
Journal:  J Neurosci Res       Date:  2003-12-15       Impact factor: 4.164

Review 8.  The role of matrix metalloproteinases in the morphogenesis of the cerebellar cortex.

Authors:  Jia Luo
Journal:  Cerebellum       Date:  2005       Impact factor: 3.648

Review 9.  Drugs in development: bisphosphonates and metalloproteinase inhibitors.

Authors:  Jon B Catterall; Tim E Cawston
Journal:  Arthritis Res Ther       Date:  2002-11-08       Impact factor: 5.156

Review 10.  Matrix metalloproteinases: old dogs with new tricks.

Authors:  Robert P T Somerville; Samantha A Oblander; Suneel S Apte
Journal:  Genome Biol       Date:  2003-05-29       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.